by Team Attomarker | Jun 29, 2026 | Company News, Long Covid
A new article, co-published by members of the Attomarker team and published in Frontiers in Virology, presents the first body of work examining the effects of chronic SARS-CoV-2 exposure, tracking the quality of antibodies produced over time in a real-world,...
by Team Attomarker | Feb 11, 2026 | Long Covid
Long Covid is still commonly approached as though it were a single condition. Patients are grouped under one label, trials recruit a single cohort, and treatments are tested as if one underlying biological mechanism were responsible. That framing was perhaps...
by Team Attomarker | Jun 10, 2025 | Long Covid
The Immune Response to SARS-CoV-2 and Long COVID Long COVID is currently reported to affect as many as one in five individuals who have had a COVID infection in the UK, with each new SARS-CoV-2 infection adding to the risk burden of developing the debilitating...
by Team Attomarker | Apr 9, 2025 | Long Covid
EXETER, UK – 4 April 2025 – Attomarker, a leader in rapid diagnostic technology, today announced its plans for a new study evaluating the use of AstraZeneca’s monoclonal antibody, Sipavibart (Kavigale), as a potential treatment for long COVID patients. Long COVID...
by Team Attomarker | Mar 13, 2025 | Long Covid
International Long COVID Awareness Day 2025 Five Years On, Long COVID Patients Are Still Being Left Behind On 15th March we mark five years since the start of the pandemic and with it, International Long COVID Awareness Day. While COVID-19 may have faded from...
by Team Attomarker | Jun 6, 2024 | Long Covid
A Novel Diagnosis and Treatment TO BOOK YOUR ANTIBODY IMMUNITY SPECTRUM TEST: Visit our clinics Elimination of a SARS-CoV-2 infection requires both antibody and T cells for complete clearance of the coronavirus from the localised infection site. Systemic...
